Evercore ISI reiterates Aura Biosciences Outperform with 238% upside (AURA)
November 27, 2025, 2:14 AM EST. Evercore ISI Group reiterated an Outperform rating on Aura Biosciences (AURA) as of Nov. 26, 2025. The target implies about 238% upside versus Aura's latest close, with a range of $17.17-$23.10 and an average target of $20.66. The forecast highlights revenue of around $6M and a non-GAAP EPS of -2.25 for the year. Fund ownership remains broad: 236 institutions hold Aura shares, with an average weight of 0.25% and total shares of 55.031M. The put/call ratio sits at 0.01, signaling a bullish tilt. Notable holders include Matrix Capital Management, Frazier Life Sciences, Adage Capital, Long Focus, and Suvretta Capital, each with multi-million share stakes.
Is Rubrik Undervalued After 37% Surge Fueled by Cloud Partnerships
November 27, 2025, 1:59 AM EST. Rubrik has climbed about 37% over the past year, even as a 2.7% dip last week and a 12.4% drop in the last month add volatility. Cloud partnerships and data-security momentum have boosted sentiment, but the stock still rates 3/6 on our undervaluation checks. Our Discounted Cash Flow (DCF) model puts an intrinsic value of about $83.14 per share, roughly 18% above the current price, suggesting Rubrik is undervalued relative to its long-term cash-flow potential. The analysis uses a two-stage FCF-to-equity framework with a projected Free Cash Flow of $765.9M by 2030. While near-term forecasts carry risk, the framework highlights a potential entry point for patient investors as growth remains robust and partnerships deepen.
SAP Share Price Dip: AI Partnerships Could Signal Opportunity Amid Undervalued Valuation
November 27, 2025, 1:56 AM EST. SAP shares have cooled after a multi-year rally, down ~12% in the last month and ~13% YTD as investors weigh growth. Headline talk of AI integrations and expanded global partnerships supports sentiment despite the pullback. A DCF view from Simply Wall St shows SAP as undervalued, with intrinsic value around €253.82 per share – about 18.6% above current levels. Forecasts project Free Cash Flow rising from €6.4B to €9.6B by 2027, with longer-term upside beyond €16.9B by 2035. The analysis notes a mid-range valuation score (3/6) and hints at a deeper dive into the method and smarter checks later. For investors, the setup suggests potential opportunity if AI-driven moats translate into durable competitive advantages.
BofA Securities Maintains Nutanix Buy Rating; PT Up ~49% to $87.65
November 27, 2025, 1:48 AM EST. BofA Securities maintained a Buy rating on Nutanix (NTNX) on November 26, 2025. The analyst price target sits at $87.65 – about 49.1% upside from the recent close of $58.77. The targets range from $71.71 to $99.75. The projection calls for $2,683M in annual revenue and a non-GAAP EPS of $1.31, down about 21.6% from prior forecasts. Fund sentiment shows 1,186 institutions holding NTNX, with average exposure near 0.25% of portfolios and total NTNX shares held rising ~4.7% to 273.4M. The put/call ratio is 0.38, pointing to a bullish tilt. Major owners include FDGRX, Vanguard funds, AQR Capital, Generation Investment Management, and NAESX, all adjusting NTNX positions last quarter.
HC Wainwright Initiates Coverage on reAlpha Tech (AIRE) with Buy; 68.8% Upside Forecast
November 27, 2025, 1:46 AM EST. HC Wainwright & Co. initiates coverage on reAlpha Tech (AIRE) with a Buy rating. The target implies about a 68.81% upside from the latest close of $0.53 to a $0.89 median one-year target, with a range of $0.50-$1.31. The projected annual non-GAAP EPS is -0.15. Fund sentiment shows 31 institutions, up 3.12% this quarter; total shares owned rose 127.57% to 3.60 million. Notable holders include Geode Capital (427K, 0.33%), Vanguard's VTSMX (290K), Virtu Financial (114K), Scientech Research (113K), and Northern Trust (109K). The update highlights broad data on fundamentals, ownership, and sentiment available on Fintel.
Peel Hunt Reiterates Buy on Diversified Energy (DEC), Signals ~86% Upside
November 27, 2025, 1:44 AM EST. Peel Hunt Limited reaffirmed its Buy stance on Diversified Energy (DEC) on November 25, 2025. The broker's latest price forecast signals ~86.74% upside from the November 17, 2025 target of $27.81, with a wide range of $14.96-$42.40 and a close around $14.89. The forecast accompanies expected annual revenue of $1,065 million and non-GAAP EPS of $0.14. On the fund side, 188 institutions hold DEC, down about 34% in the quarter, with average weights near 0.11% and total shares around 37.4 million (−3.3% QoQ). Major holders include Ameriprise (4.109M), COAVX (2.644M), Citadel Advisors (2.379M), Tejara (1.953M), and M&G (1.915M). The note also points to Fintel's research resources.
Nifty50 hits lifetime high near 26,300; Sensex tops 86,000 on bullish setup
November 27, 2025, 1:42 AM EST. Stocks built on a bullish tone as Indian benchmarks extended gains, with Nifty50 briefly crossing 26,300 and BSE Sensex around 85,900. At 10:19 AM, Nifty stood at 26,278 (+0.28%), while the Sensex traded near 85,900 (+0.34%). Analysts point to improving Q3 demand, capex prospects, and expectations of rate cuts from the RBI and the US Federal Reserve as catalysts for further upside. In global markets, US equities rose on rate-cut hopes, while Asian peers followed higher. Gold steadied after a prior peak. FPIs remained net buyers, supported by domestic institutions. Cautious near-term patience advised, as valuation and festival-season moderation could cap gains, but a further rally remains possible if earnings momentum sustains.
Jefferies Maintains Buy on Nektar Therapeutics (NKTR) with ~58.6% Upside to $95.73 Target
November 27, 2025, 1:33 AM EST. Jefferies reiterates a Buy rating on Nektar Therapeutics (NKTR). As of Nov. 17, 2025, the firm's average one-year price target stands at $95.73, implying ~58.6% upside from NKTR's close of $60.35 on Nov. 26, 2025. Targets range from $30.30 to $126.00. The company's projected annual revenue is $100M (↑~59.9%), while estimated non-GAAP EPS is -1.19. On fund sentiment, 218 funds/institutions own NKTR, up ~78.7% quarter over quarter; average weight 0.23%; total shares held ~15.19M (↑97.3%). The put/call ratio sits at 0.25, signaling bullishness. Top holders include BVF (1.28M, 6.28%), Susquehanna (0.93M), Farallon (0.79M), Millennium (0.55M), and Two Sigma (0.43M). Source: Fintel.
Citigroup Initiates Coverage on Nektar Therapeutics (NKTR) with Buy; ~58.6% Upside to $95.73
November 27, 2025, 1:30 AM EST. Citigroup has initiated coverage of NKTR with a Buy rating. The target price implies about a 58.63% upside to the latest close, with an average one-year target of $95.73 (range $30.30-$126.00). That compares with a $60.35 close, implying a ~58.63% lift. Fintel notes projected annual revenue of $100MM and non-GAAP EPS of -1.19. Fund sentiment remains constructive: 218 funds own NKTR, up 78.69% this quarter, with average weight 0.23% and total shares at 15,187K. The put/call ratio is 0.25. Major holders include Bvf, Susquehanna, Farallon, Millennium, and Two Sigma.
Barrington Research Maintains PowerFleet (AIOT) Outperform; 131% Upside Implied
November 27, 2025, 1:28 AM EST. Barrington Research has maintained an Outperform rating on PowerFleet (AIOT), signaling continued conviction for the IoT fleet-management company. The firm's latest forecast points to an average one-year target of $10.88, implying about 131.49% upside from the late-November price of $4.70. The target range spans $8.08-$15.75. Upcoming metrics include projected annual non-GAAP EPS of 0.34. Asset-manager sentiment remains constructive: 347 funds hold AIOT, with a collective 0.25% portfolio weight and roughly 133,053K shares owned. The put/call ratio sits at 0.04, underscoring a bullish tilt. Notable holders include Private Capital Management, Disciplined Growth Investors, Voss Capital, Private Management Group, and AWM Investment, each with multi-million share stakes.
Goldman Sachs Maintains Buy on Broadcom (AVGO) with Modest Upside
November 27, 2025, 1:16 AM EST. Goldman Sachs reaffirmed a Buy rating on Broadcom (AVGO) on November 26, 2025. The firm's target implies about a 3.06% upside to the November 17 target of $396.82 per share, from a current close around $385.03. The one-year target range spans $220.18-$504.00. Investors should note the sentiment signals: the put/call ratio sits at 1.04, pointing to a bearish tilt, though funds remain broadly positioned. Institutional holders total 4,284,169K shares across 6,286 funds, with an average portfolio weight of 1.63% for AVGO, up roughly 11.17% quarter over quarter. Notable owners include Vanguard, Capital International, Capital World Investors, and Geode Capital. Fintel provides comprehensive data on ownership, sentiment, and more.
HC Wainwright Reiterates BiomX Buy; 173% Upside to $15.81 Target (PHGE)
November 27, 2025, 1:14 AM EST. HC Wainwright & Co. reiterates a Buy rating on BiomX (PHGE). The analyst price forecast points to a 173.53% upside with a target of $15.81 versus a $5.78 close. The one-year target range sits at $15.15-$16.80. The article notes a fund sentiment shift: 22 institutions hold PHGE, with an average portfolio weight of 0.01% and total PHGE shares of about 8.311 million (down 23.32% in three months). Major holders include Deerfield Management (2,494K; 163.37% ownership) and Nantahala (2,493K; 163.32%). Other owners: Alyeska (1,591K; 104.20%) and JPMorgan Chase (430K; 28.17%). The model shows 0MM revenue and -0.81 non-GAAP EPS for BiomX.
Tianyu Semiconductor launches $215M IPO as China market briefs highlight IPOs, fundraises and earnings shifts
November 27, 2025, 1:13 AM EST. China market briefs show active fundraising and shifting earnings across names. Tianyu Semiconductor launches a $215 million IPO, joining a slate that includes Xiao Noodles' Hong Kong IPO up to $89 million. Results are mixed: Baozun narrows operating profit as its e-commerce unit returns to profitability, while Noah Holdings posts a 63% profit jump despite weaker revenue. In financing rounds, Minieye seeks up to $26 million via a 10% discounted placement, and Ubtech targets about $400 million in a placement at an 11.4% discount. On the demand side, Cathay Pacific traffic rises; Luckin Coffee eyes global expansion, potentially pursuing Costa Coffee. So-Young, CSPC, and Yum China signal shifts to new formats, price pressures, and a bold 2030 expansion plan.
RadNet (RDNT): Valuation Near Fair Value as Momentum Builds
November 27, 2025, 1:09 AM EST. RadNet (RDNT) shares have quietly built momentum, with a 15.3% gain over 90 days and an 18% YTD rise, while a 318.8% three-year TSR underscores a long-run reward for early investors. The stock trades near a fair value of $86.67 vs a recent close around $82.79, suggesting a modest undervaluation as markets price in next-gen growth. Analysts factor in big future revenue and margin leaps, supported by aggressive expansion and a major digital health push with AI-powered imaging (DeepHealth, See-Mode, iCAD) boosting throughput and high-margin procedures. Risks include possible reimbursement headwinds that could cap margin gains and slow growth. The P/S ratio at 3.2x vs peers around 1.1x raises questions about upside; deeper numbers await in the narrative.
JPMorgan Upgrades ATMU to Overweight; $54.26 PT Signals ~13% Upside
November 27, 2025, 12:56 AM EST. JPMorgan has upgraded Atmus Filtration Technologies (ATMU) from Neutral to Overweight, signaling a more bullish view. The firm's price target sits at $54.26, implying ~12.98% upside from the latest close of $48.03, with a target range of $45.45 to $61.95. Projected annual revenue is $1,769MM and non-GAAP EPS is $2.31. The data point to strong institutional interest: about 638 funds own ATMU, with total shares held rising to ~102.1M and a put/call ratio of 0.05. Notable holders include Eminence Capital (8.00%), Price T. Rowe Associates (5.01%), Goldman Sachs (3.73%), Vanguard (3.28%), and Geode Capital (2.91%). The upgrade could lift attention on ATMU ahead of earnings and product news.
Nasdaq ISE Seeks to Quadruple IBIT Options Limits on BlackRock Bitcoin ETF
November 27, 2025, 12:22 AM EST. Nasdaq's International Securities Exchange (ISE) has filed with the SEC to raise IBIT options position limits from 250,000 to 1,000,000 contracts and to remove caps on customized FLEX options that are physically delivered. The plan would place IBIT on par with major equities and ETFs, boosting market depth and liquidity for institutional traders and market makers. Analysts say the higher limits could support larger, lower-risk allocation strategies and potentially compress volatility over the next year. The proposal highlights IBIT's $86.2 billion market cap and about 44.6 million shares of average daily volume. Public comments run through December 17, 2025, and SEC approval remains required before any changes take effect.
MINISO (NYSE:MNSO) Valuation Under Review After Strong Sales Growth and Upbeat Guidance
November 27, 2025, 12:08 AM EST. MINISO Group Holding (NYSE:MNSO) delivered strong sales growth in Q3 while net income declined, and issued positive earnings guidance. The stock has been volatile, with a sharp pullback in the past month, even as long-term total shareholder return remains solid (about 9% over one year, ~79% over three years). The setup points to a market weighing rapid top-line expansion against near-term profit pressures. Analysts note the stock trades ~40% below its average target of around $26.69, suggesting potential undervalued status if expansion remains on track. A key catalyst is store expansion, especially overseas, with MINISO targeting 900-1,100 net new stores in 2024 and a sizable international footprint. Risks include missteps in rapid rollout and underperforming super stores.
Kodiak Gas Services: NYSE Texas Dual Listing Sparks Valuation Review
November 27, 2025, 12:07 AM EST. Kodiak Gas Services (KGS) kicked off trading on NYSE Texas after announcing a dual listing, alongside a 10 million share offering and a plan to repurchase 1 million shares. The stock has drifted lower in 2024 (YTD -16.38%) but posted a 1-week gain of 3.47%, signaling fresh interest. The 1-year total shareholder return is -7.81%, underscoring a mixed setup where recent momentum could reflect shifting sentiment amid the new market access and capital actions. Analysts see upside with a fair value around $44.20 versus a close near $34.93, yet the stock trades at a P/E near 40x, well above energy services peers. Risks include labor shortages in the Permian, regulatory pressures, and execution risks of the rollout.
